CVS Health Corporation $CVS Shares Sold by Integral Health Asset Management LLC

Key Points

• Integral Health Asset Management trimmed its CVS stake by 20.0%, selling 50,000 shares and leaving 200,000 shares worth $15.078 million (about 1.0% of its portfolio).
• CVS beat quarterly expectations with $1.09 EPS vs $1.00 expected and $105.69B revenue (up 8.2% YoY), set FY2026 EPS guidance of 5.940–6.140, and carries a consensus "Moderate Buy" from analysts with an average target of $95.05.
• Mixed catalysts: CVS is rolling out an AI‑powered health platform and gaining menopause accreditation, but faces legal and policy risks including an Aetna $117.7M DOJ settlement and threats to close 100+ Tennessee pharmacies if PBM legislation passes.

Integral Health Asset Management LLC reduced its position in CVS Health Corporation (NYSE:CVS - Free Report) by 20.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 200,000 shares of the pharmacy operator's stock after selling 50,000 shares during the quarter. CVS Health comprises approximately 1.0% of Integral Health Asset Management LLC's portfolio, making the stock its 27th biggest position. Integral Health Asset Management LLC's holdings in CVS Health were worth $15,078,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. acquired a new position in CVS Health in the second quarter valued at $1,651,000. Allworth Financial LP raised its stake in shares of CVS Health by 3.9% during the second quarter. Allworth Financial LP now owns 26,842 shares of the pharmacy operator's stock worth $1,852,000 after purchasing an additional 1,017 shares during the last quarter. Boston Partners purchased a new position in CVS Health in the 2nd quarter valued at $3,324,000. Jupiter Asset Management Ltd. acquired a new position in CVS Health in the 2nd quarter valued at $7,512,000. Finally, PNC Financial Services Group Inc. raised its holdings in CVS Health by 1.5% during the second quarter. PNC Financial Services Group Inc. now owns 568,176 shares of the pharmacy operator's stock worth $39,193,000 after purchasing an additional 8,407 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $76.14 on Friday. The company has a market cap of $96.87 billion, a P/E ratio of 55.17, a P/E/G ratio of 0.79 and a beta of 0.49. The business has a fifty day simple moving average of $78.17 and a 200-day simple moving average of $77.74. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion for the quarter, compared to analysts' expectations of $103.67 billion. During the same period last year, the company earned $1.19 earnings per share. The company's quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health's dividend payout ratio (DPR) is 192.75%.

Analysts Set New Price Targets

CVS has been the topic of several recent analyst reports. The Goldman Sachs Group boosted their target price on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $93.00 to $101.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 17th. Truist Financial set a $100.00 price target on shares of CVS Health in a research note on Wednesday, December 10th. Argus reduced their price target on shares of CVS Health from $91.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday, January 28th. Finally, Wolfe Research decreased their price target on CVS Health from $100.00 to $97.00 and set an "outperform" rating on the stock in a research note on Monday, March 2nd. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and an average target price of $95.05.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to "outperform" with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors' radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.